Treatment of benign prostatic hyperplasia and prevention of urological complications in order to reduce the risk of acute urinary retention, reduce the risk of the need for surgical interventions, including transurethral resection of the prostate and prostatectomy.
Treatment to reduce the size of an enlarged prostate, improve urination, and reduce the severity of symptoms associated with benign prostatic hyperplasia.
In combination with doxazosin-reducing the risk of progression of symptoms associated with benign prostatic hyperplasia.
Hypersensitivity to finasteride; age under 18 years; pregnancy and use of finasteride in women of childbearing age (see "Use during pregnancy and lactation").
Use during pregnancy and lactation
The use of finasteride is contraindicated during pregnancy and women of childbearing age. Due to the ability of type II 5-alpha-reductase inhibitors to inhibit the conversion of testosterone to DHT, these drugs, including finasteride, when used in pregnant women can cause abnormalities in the development of the external genitalia in the male fetus.
Finasteride is not indicated for use in women.
There are no data on the excretion of finasteride in breast milk.
Small amounts of finasteride were found in the semen of patients treated with finasteride at a dose of 5 mg / day. Although there is no clinical data on the effect of finasteride on the male fetus, women of childbearing age should avoid contact with the seminal fluid of men taking finasteride. Women of childbearing age and pregnant women should avoid contact with damaged finasteride tablets, since its ability to suppress the conversion of testosterone to DHT can cause a violation of the development of the genitals in the male fetus.
The category of action on the fetus according to the FDA is X.
Adverse reactions to finasteride are divided into system-organ classes according to the MedDRA classification. The frequency of adverse reactions was determined according to the following gradation (WHO classification): very common (≥1/10); common (≥1/100, <1/10); infrequent (≥1/1000, <1/100); rare (≥1/10000, <1/1000); very rare (<1/10000), including individual reports; frequency unknown (frequency cannot be determined, since information is obtained on the basis of post-marketing experience with finasteride).
Most often, patients experienced impotence and decreased libido, although the frequency of these side effects gradually decreased during treatment.
|Active ingredient, mg||5|
|1 pill, mg||5|
|Blister, pills||3, 20|
|Packing||Packing (3 blisters), Blister (20 pills)|